Hypothesize That!

In this special Crimes Against Innovation episode, host Nicola Hill hears two charges against pharma.

Erik Janssen, UCB’s Vice President and Head of Digital Care Transformation, argues that ‘pilotitis’ is 'the most expensive way to look innovative’, with organizations trapped in pilots that generate excitement but fail to create meaningful change at scale. Meanwhile, healthcare innovation expert Gary Monk presents the crime of ‘not invented here’, where pharma organizations choose to build solutions themselves rather than drawing on existing expertise, often wasting time and money on tools that may not meet patient needs.

Which innovation crime is causing the most damage? Join the debate and decide which crime should carry the greater sentence.

Hosted on Acast. See acast.com/privacyhttps://acast.com/privacy for more information.

This podcast is produced and funded by UCB.

[GL-DA-2600935] – October 2026

Hosted on Acast. See acast.com/privacy for more information.

AI can already diagnose some conditions faster than humans. Robots are entering hospitals. So, are we heading towards a future without doctors?

Nicola Hill sits down with UCB's Vice President and Head of Digital Care Transformation, Erik Janssen and healthcare innovation expert Gary Monk to debate one of healthcare’s biggest questions: what happens when technology becomes capable of doing more of today’s clinical work?

Together, they explore how AI, digital health technologies and connected data could help patients access the right care sooner and improve outcomes, while supporting clinicians to focus on the human aspects of care, including empathy, trust and shared decision-making.

Listen to discover what role clinicians play in the healthcare systems of tomorrow, and why the future may be closer than many people think.

*This podcast is produced and funded by UCB. It does not constitute medical advice. Always consult a healthcare professional regarding health matters.

Hosted on Acast. See acast.com/privacyhttps://acast.com/privacy for more information.

This podcast is produced and funded by UCB.

[GL-DA-2600935] - October 2026

Hosted on Acast. See acast.com/privacy for more information.

In this episode, we ask a defining question: will multi-specific therapies revolutionize how we treat complex diseases? Host Nicola Hill is joined by Dr Joe Rastrick (UCB) and Professor Raj Chovatiya (Rosalind Franklin University) to examine whether medicines engineered to target multiple pathways can be more effective and personalized than current single-target or broad-spectrum approaches.

Discover how by leveraging combinatorial biology, researchers are working on designing therapies that have more precise targeting, focusing only on the pathways driving disease, while avoiding the ones that maintain health. The episode also discusses practical barriers, from molecule complexity to immunogenicity, trial design and regulatory uncertainty.

This podcast is produced and funded by UCB. It discusses combination therapies for informational purposes only. It does not constitute medical advice. Always consult a healthcare professional regarding health matters and prescription medicines and follow the label guidelines.

Hosted on Acast. See acast.com/privacyhttps://acast.com/privacy for more information.

GL-OT-2600004 – May 2026

Hosted on Acast. See acast.com/privacy for more information.

In this special Crimes Against Innovation episode, host Nicola Hill hears two charges against the research system.

Professor Raj Chovatiya argues that the academic model is putting the brakes on innovation, squeezing creativity and collaboration. Meanwhile, Dr Joe Rastrick condemns the irreproducible published study, which can misdirect future research and waste resources.

Join the debate and decide which crime should carry the greater sentence.

Hosted on Acast. See acast.com/privacyhttps://acast.com/privacy for more information.

This podcast is produced and funded by UCB.

GL-OT-2600004 – May 2026

Hosted on Acast. See acast.com/privacy for more information.

In this episode, host Nicola Hill, is joined by Professor Maddie Parsons, Dean of Research Excellence Frameworks at King’s College London, and Dr Graham Price, Head of Global Clinical Development at UCB, to examine whether today’s trials are fit for tomorrow’s science.

Listen to our guests unpick the tensions in modern drug development from conservative endpoints, missed opportunities and lack of integration across clinical and scientific disciplines. Can smarter design, better data sharing, and deeper collaboration unlock the future of precision medicine?

This podcast is produced and funded by UCB.

Hosted on Acast. See acast.com/privacy for more information.

GL-OT-2600003 – March 2026

Hosted on Acast. See acast.com/privacy for more information.

Deep in the shadowy corridors of laboratories and the silent pages of medical journals, progress can falter, not for lack of brilliance, but because of the systems surrounding it. Ideas are delayed, discoveries are hidden, and bold thinking is quietly discouraged. This is Crimes Against Innovation.

Join Professor Maddie Parsons and Dr Graham Price as they go head-to-head on two major offenders in healthcare innovation. Maddie argues that playing it safe and avoiding high-risk research is suppressing transformative breakthroughs, while Graham challenges that the bigger crime is secrecy in science - a true assassin of progress.

Host Nicola Hill weighs the evidence and delivers the verdict on which of these “crimes” does the greatest damage to discovery.

This podcast is produced and funded by UCB.

Hosted on Acast. See acast.com/privacy for more information.

This podcast is produced and funded by UCB.

GL-OT-2600003 – March 2026

Hosted on Acast. See acast.com/privacy for more information.

Is scientific innovation enough to drive the future of gene therapy, or is patient engagement the missing key? Join host Nicola Hill as she explores this question with Laurence Woollard, a rare disease advocate, and UCB’s Global Patient Engagement Lead, Dr. Emma Lane. Together, they discuss the critical role of patients in co-creating therapies that meet real-world needs, the ethical challenges of gene editing, and how early collaboration can build trust and transparency. Hear real-world insights into how patient voices are reshaping R&D—and how industry can embrace this paradigm shift.

This podcast is produced and funded by UCB.

Hosted on Acast. See acast.com/privacy for more information.

IE-OT-2500003 – July 2025

Hosted on Acast. See acast.com/privacy for more information.

In the darkened corridors of laboratories and the silent pages of medical journals, there are stories rarely spoken about—tales of brilliance that burned too bright, and ideas that strayed into catastrophe. This is—Crimes Against Innovation.

Laurence Woollard and Dr. Emma Lane debate two pressing issues in healthcare: the under-representation of women in clinical trials and the misleading timelines often promised for new treatments. Host Nicola Hill listens to both sides and selects the most impactful “crime” against innovation.

This podcast is produced and funded by UCB.

Hosted on Acast. See acast.com/privacy for more information.

IE-OT-2500003 – July 2025

Hosted on Acast. See acast.com/privacy for more information.

In the shadowy corridors of laboratories and the silent pages of medical journals, there lie tales that have seldom been told. Tales of ambition that flew too close to the sun, of genius that turned into folly, and of innovation that... well, wasn't quite so innovative. This is—Crimes Against Innovation.

Join Craig Lipset and Lewis Millen as they argue two distinct crimes against innovation. Lewis takes on the Theranos scandal, a cautionary tale of deceit in healthcare, while Craig reflects on how corporate culture can slow down and even stop innovation trials. Host Nicola Hill must choose the most compelling case.

This podcast is produced and funded by UCB.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

In this episode, host Nicola Hill explores the hypothesis that fully virtualised decentralized clinical trials (DCT), that operate invisibly, will make traditional models obsolete within the next decade.

Joining her are Craig Lipset, Co-Chair of the Decentralized Trials and Research Alliance, and Lewis Millen, UCB’s Global Clinical Science and Operations Innovation Lead. Together, they unpack the plausibility, benefits and challenges of this shift, from inclusivity and patient convenience to technological hurdles and regulatory readiness. Is a hybrid model the future, or will decentralized clinical trials render old paradigms irrelevant?

This podcast is produced and funded by UCB.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.